Effect of telmisartan on walking performance in patients with lower extremity peripheral artery disease. The TELEX Randomized Clinical Trial.
McDermott M, Bazzano L, Peterson CA, Sufit R, Ferrucci L, Domanchuk K et al.
JAMA 2022; 328: 1315-1325.
After six months, Telmisartan, an angiotensin receptor blocker, did not improve six-minute walking distance compared with placebo in this study that included 114 patients (P=0.08).
Comment: Still no good medicines for claudication.
24 November 2022
Read paperAcademy
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
